Navigation Links
Hematide in Medical Technology

Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia

PALO ALTO, Calif.--(BUSINESS WIRE)--Jun 25, 2007 - Affymax, Inc. (Nasdaq:AFFY) today announced that additional Phase 2 clinical trial results for Hematide(TM) were presented at the European Renal Association-EDTA Congress being held in Barcelona, Spain by Iain C. Macdougall, M.D., a Hematide invest...

Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia

...rt Takeda's efforts in the clinical development of hematide in chemotherapy induced anemia. We are pleased wit...etics and preliminary efficacy of various doses of hematide in the correction of anemia. Initial dosing in thi...al later stage clinical trials. About Hematide hematide is a novel synthetic, pegylated peptidic compound ...

Affymax Announces Results From Phase 2 Clinical Trial of Hematide for the Treatment of Anemia in Dialysis Patients

...s safety, pharmacodynamics and pharmacokinetics of hematide in hemodialysis patients with stable baseline Hgb ...y. The endpoints were Hgb and reticulocyte levels, hematide dose adjustments and red blood cell transfusions. ...n reticulocyte increases were observed after every hematide injection. The mean Hgb level, which was 11.5 g/dL...

Affymax Announces Phase 2 Clinical Trial Results of Once-Per-Month Hematide for the Treatment of Anemia in Patients with Early- and End-Stage Chronic Kidney Disease

...wed that in treatment naive, non-dialysis patients hematide could correct anemia when administered monthly at ...evels following a switch to once monthly dosing of hematide at an appropriate dose. The data were presented by...ing held in Rio de Janeiro. "These data show that hematide results in appropriate management of hemoglobin le...
Hematide in Biological Technology

Nektar's PEGylation Technology Enables Peptide Mimetic, Highlighted by Data Presented at 45th ERA-EDTA Congress

...uddock (650) 631-4954 or jruddock@nektar.com References (1) MacDougall I. et al, Interim evaluation of long-term safety and tolerability of hematide during maintenance treatment of anaemia in patients with chronic kidney disease, presented on 12 May 2008 at the 45th ERA-EDTA congress, Sto...

Affymax(R) and Takeda Recognized for Innovative Global Agreement to Develop and Commercialize Hematide(TM) for Anemia

...izes our strategic alliance with Takeda to develop hematide worldwide as a potential treatment for anemia asso...x and Takeda have made significant progress in the hematide clinical development program. We recently initiate...tegy. We look forward to continued progress in the hematide clinical development program." Affymax and Takeda...
Other Tags
(Date:10/2/2014)... When a child, deaf person or elderly ... keep them from wandering off. "In order to eliminate this ... three inventors from Yulee, Fla. , The BUZZ ME helps ... and deters them from wandering off. This avoids stress and ... use and compact, the device can be produced in design ...
(Date:10/2/2014)... 2014 The Business Intelligence Group ... Awards for Business program. The BIG Awards specialize ... proprietary judging process scored by well-known and experienced ... “The winners this year epitomize what is going ... of the Business Intelligence Group. “The sheer amount ...
(Date:10/2/2014)... News) -- Scientists have pinpointed a molecule that may ... The researchers say this finding could offer a ... these attacks. Most asthma attacks (80 percent to ... airways, according to the British researchers. Most of these ... common cold. The researchers found that a specific ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, 2014 (HealthDay News) ... -- may face an increased risk of dying in the next ... 3,000 older Americans, researchers found those who were unable to detect ... times as likely to die in the next five years, versus ... -- the inability to distinguish odors -- was a bigger predictor ...
(Date:10/1/2014)... is strongly associated with Alzheimer,s disease; however, researchers are ... the causal agent of the onset and development of ... that beta-amyloid is not harmful when found in isolation ... self-assembles to form the so-called amyloid fibrils , "We ... but with multiple ones because each aggregate of peptide, ...
Breaking Medicine News(10 mins):Health News:Innovation Dominant Theme among 2014 Big Awards for Business Winners and Finalists 2Health News:New Clues to How Colds Can Spur Asthma Attacks 2Health News:Could a Fading Sense of Smell Point to Earlier Death? 2Health News:Could a Fading Sense of Smell Point to Earlier Death? 3Health News:Laying siege to beta-amyloid, the key protein in Alzheimer's disease 2
(Date:10/1/2014)... , October 1, 2014 ... the life science field  The life ... and go over the years. Some are shooting ... upconversion is a novel detection technology that has ... Now, finally, this technology is becoming commercially available. ...
(Date:9/30/2014)... nature as something that we enjoy when we visit a ... we think of ourselves as a part of nature? A ... a house? , The answers to these questions reflect ... our speech and in cultural artifacts. , A new Northwestern ... American Indian Center of Chicago and the Menominee tribe of ...
(Date:9/30/2014)... JOLLAJoseph Ecker, a Salk professor and Howard Hughes ... scientist, have been named recipients in the 2014 ... Health (NIH) through the BRAIN (Brain Research through ... neuroscience. The grant, announced September 30, provides more ... scientists over three years. , The BRAIN Initiative, ...
Breaking Biology News(10 mins):First-of-a-kind Solution for Utilizing Photon Upconversion 2The cultural side of science communication 2Salk scientists receive $3 million for BRAIN Initiative grant 2
Other Contents